PDF
ePub
Citation
Print
Seung IL Jung, Chul Woong Youn, Taek Won Kang, Dong Deuk Kwon, Kwangsung Park
, Soo Bang Ryu
, Soo Bang Ryu
Abstract
Purpose
We wanted to investigate how transurethral resection of the prostate (TURP), for treating patients with benign prostate hyperplasia (BPH), affected the serum prostate-specific antigen (PSA) levels.
Materials and Methods
The serum PSA levels were measured before and 12 months after operation in 57 patients who underwent TURP for BPH. The total prostate weight, as measured by transurethral ultrasonography (TRUS), and the weight of the surgical specimen were examined in relation to the pretreatment PSA value and the changes in the PSA levels after the operation.
Results
The preoperative mean PSA density was 0.10±0.08ng/ml/cc. The postoperative serum PSA levels were decreased significantly after TURP (p=0.002). Removal of 1g of BPH tissue reduced the serum PSA levels by an average of 0.22±0.4ng/ml. The changes in the serum PSA level one year after TURP correlated with the resected chip weights [Y=0.406+0.176x (r=0.526, p<0.05)].
Figures and Tables
Fig. 1
The relationship between the changes in the prostate-specific antigen (PSA) level and the resected volume in the patients suffering with benign prostatic hyperplasia (BPH) (Y=0.406+0.176x) (r=0.526, p<0.05), n=57.
References
1. Wang MC, Valenzuela LA, Murphy GP, Chu TM. Purification of a human prostate specific antigen. Invest Urol. 1979. 17:159–163.
2. Catalona WJ, Richie JP, Ahmann FR, Hudson MA, Scardino PT, Flanigan RC, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994. 151:1283–1290.
3. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: What happened in the last 20 years? J Urol. 2004. 172:1297–1301.
4. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E. Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med. 1987. 317:909–916.
5. Vesey SG, Goble NM, Stower MJ, Hammonds JC, Smith PJ. The effects of transurethral prostatectomy on serum prostate specific antigen. Br J Urol. 1988. 62:347–351.
6. Aus G, Bergdahl S, Frosing R, Lodding P, Pileblad E, Hugosson J. Reference range of prostate-specific antigen after transurethral resection of the prostate. Urology. 1996. 47:529–531.
7. Furuya Y, Akakura K, Tobe T, Ichikawa T, Igarashi T, Ito H. Changes in serum prostate-specific antigen following prostatectomy in patients with benign prostate hyperplasia. Int J Urol. 2000. 7:447–451.
8. Bostwick DG, Cooner WH, Denis L, Jones GW, Scardino PT, Murphy GP. The association of benign prostatic hyperplasia and cancer of the prostate. Cancer. 1992. 70:291–301.
9. Schwartz I, Wein AJ, Malloy TR, Glick JH. Prostatic cancer after prostatectomy for benign disease. Cancer. 1986. 58:994–996.
10. Won JJ, Chung HC, Song JM. The significance of changes in serum prostate specific antigen levels after a transurethral resection of the prostate. Korean J Urol. 2005. 46:704–707.
11. Jeung HJ, Oh BR, Moon JD. The effect on serum prostate specific antigen after transurethral resection of prostate for benign prostate hypertrophy. Korean J Urol. 1997. 38:70–75.
12. Kim DW, Ryu DS, Oh TH. Effect of transurethral surgery on serum percent free prostate-specific antigen levels. Korean J Urol. 2003. 44:272–277.
13. Choi UB, Song JM. Effects of digital rectal examination and transurethral resection of the prostate on serum prostate-specific antigen and acid phosphatase levels. Korean J Urol. 1993. 34:61–67.
14. Epstein JI, Walsh PC, Carmichael M, Brendler CB. Pathological and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer. JAMA. 1994. 271:368–374.
15. Byar DP, Mostofi FK. Carcinoma of the prostate: prognostic evaluation of certain pathologic features in 208 radical prostatectomies. Cancer. 1972. 30:5–13.
16. Lloyd SN, Collins GN, McKelvie GB, Hehir M, Rogers AC. Predicted and actual change in serum PSA following prostatectomy for BPH. Urology. 1994. 43:472–479.
17. Nadler RB, Humphrey PA, Smith DS, Catalona WJ, Ratliff TL. Effect of inflammation and benign prostatic hyperplasia on elevated serum prostate specific antigen levels. J Urol. 1995. 154:407–413.
18. Lepor H, Wang B, Shapiro E. Relationship between prostatic epithelial volume and serum prostate-specific antigen levels. Urology. 1994. 44:199–205.
19. Marks LS, Dorey FJ, Rhodes T, Shery ED, Rittenhouse H, Partin AW, et al. Serum prostate specific antigen levels after transurethral resection of prostate: a longitudinal characterization in men with benign prostatic hyperplasia. J Urol. 1996. 156:1035–1039.
20. Lee SC, Lee SC, Kim WJ. Value of PSA density, PSA velocity and percent free PSA for detection of prostate cancer in patients with serum PSA 4-10ng/ml patients. Korean J Urol. 2004. 45:747–752.
21. Moon DG, Yu JW, Cheon J, Yoon DK. The efficacy of prostate specific antigen adjusted for the transition zone volume (PSATZ) as a new predictor of prostatic cancer. Korean J Urol. 1999. 40:575–582.
XML Download